JTR-161

Drug Profile

JTR-161

Alternative Names: Dental pulp stem cells - JCR; DPCs-JCR; JR-161

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JCR Pharmaceuticals
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cerebral infarction

Most Recent Events

  • 18 Jul 2017 JCR Pharmaceuticals plans clinical development for Cerebral infarction in Japan in 2018
  • 18 Jul 2017 JCR Pharmaceuticals and Teijin agree to co-promote and co-develop JTR-161 in Japan for Cerebral infraction
  • 18 Jul 2017 Preclinical trials in Cerebral infarction in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top